Deutsche Bank Cuts CME Group (CME) Price Target to $214.00

CME Group (NASDAQ:CME) had its price objective decreased by equities researchers at Deutsche Bank from $220.00 to $214.00 in a research report issued to clients and investors on Friday. The brokerage presently has a “buy” rating on the financial services provider’s stock. Deutsche Bank’s price target would indicate a potential upside of 26.07% from the company’s current price.

Several other research firms have also issued reports on CME. Citigroup assumed coverage on shares of CME Group in a report on Tuesday, November 20th. They issued a “buy” rating and a $220.00 target price for the company. Berenberg Bank raised shares of CME Group from a “hold” rating to a “buy” rating and set a $220.00 target price for the company in a report on Tuesday, November 20th. Atlantic Securities assumed coverage on shares of CME Group in a report on Wednesday, November 28th. They issued a “neutral” rating and a $200.00 target price for the company. UBS Group lowered shares of CME Group from a “buy” rating to a “neutral” rating and increased their target price for the stock from $185.00 to $204.00 in a report on Wednesday, November 28th. Finally, Keefe, Bruyette & Woods reissued a “hold” rating and issued a $184.00 target price on shares of CME Group in a report on Monday, December 10th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $194.00.

Shares of NASDAQ CME traded up $1.32 during midday trading on Friday, hitting $169.75. 45,473 shares of the company’s stock traded hands, compared to its average volume of 1,859,918. CME Group has a 1 year low of $153.90 and a 1 year high of $197.08. The firm has a market capitalization of $60.12 billion, a P/E ratio of 24.88, a PEG ratio of 2.15 and a beta of 0.31. The company has a quick ratio of 1.01, a current ratio of 1.01 and a debt-to-equity ratio of 0.15.

CME Group (NASDAQ:CME) last released its quarterly earnings results on Thursday, February 14th. The financial services provider reported $1.77 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.75 by $0.02. CME Group had a net margin of 45.53% and a return on equity of 9.85%. The firm had revenue of $1.24 billion during the quarter, compared to analyst estimates of $1.22 billion. During the same quarter in the prior year, the firm earned $1.12 EPS. The business’s revenue for the quarter was up 37.4% compared to the same quarter last year. As a group, equities research analysts anticipate that CME Group will post 7.07 EPS for the current year.

In other news, Director Ronald A. Pankau sold 200 shares of the stock in a transaction that occurred on Friday, March 1st. The stock was sold at an average price of $182.90, for a total transaction of $36,580.00. Following the completion of the transaction, the director now directly owns 3,600 shares in the company, valued at approximately $658,440. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Julie Holzrichter sold 4,362 shares of the stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $182.45, for a total value of $795,846.90. Following the transaction, the chief operating officer now owns 41,265 shares of the company’s stock, valued at $7,528,799.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 32,609 shares of company stock valued at $5,984,391. Insiders own 0.43% of the company’s stock.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sheaff Brock Investment Advisors LLC lifted its position in shares of CME Group by 0.3% during the fourth quarter. Sheaff Brock Investment Advisors LLC now owns 22,040 shares of the financial services provider’s stock worth $4,146,000 after purchasing an additional 60 shares during the last quarter. Dorsey & Whitney Trust CO LLC increased its stake in shares of CME Group by 1.4% during the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 4,575 shares of the financial services provider’s stock valued at $860,000 after buying an additional 65 shares during the period. Private Trust Co. NA increased its stake in shares of CME Group by 1.9% during the fourth quarter. Private Trust Co. NA now owns 3,488 shares of the financial services provider’s stock valued at $656,000 after buying an additional 66 shares during the period. Front Barnett Associates LLC increased its stake in shares of CME Group by 5.4% during the fourth quarter. Front Barnett Associates LLC now owns 1,433 shares of the financial services provider’s stock valued at $267,000 after buying an additional 73 shares during the period. Finally, Ascension Asset Management LLC increased its stake in shares of CME Group by 0.6% during the fourth quarter. Ascension Asset Management LLC now owns 12,385 shares of the financial services provider’s stock valued at $2,330,000 after buying an additional 75 shares during the period. Hedge funds and other institutional investors own 88.49% of the company’s stock.

About CME Group

CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural products, and metals.

Featured Article: What is the Dow Jones Industrial Average (DJIA)?

Analyst Recommendations for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.